SI2768484T1 - Liofilizirani liposomi - Google Patents
Liofilizirani liposomiInfo
- Publication number
- SI2768484T1 SI2768484T1 SI201231668T SI201231668T SI2768484T1 SI 2768484 T1 SI2768484 T1 SI 2768484T1 SI 201231668 T SI201231668 T SI 201231668T SI 201231668 T SI201231668 T SI 201231668T SI 2768484 T1 SI2768484 T1 SI 2768484T1
- Authority
- SI
- Slovenia
- Prior art keywords
- lyophilized liposomes
- liposomes
- lyophilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161550047P | 2011-10-21 | 2011-10-21 | |
EP12841616.1A EP2768484B1 (en) | 2011-10-21 | 2012-10-15 | Lyophilized liposomes |
PCT/US2012/060293 WO2013059133A1 (en) | 2011-10-21 | 2012-10-15 | Lyophilized liposomes |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2768484T1 true SI2768484T1 (sl) | 2019-12-31 |
Family
ID=48141268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201231668T SI2768484T1 (sl) | 2011-10-21 | 2012-10-15 | Liofilizirani liposomi |
Country Status (22)
Country | Link |
---|---|
US (5) | US10028912B2 (sl) |
EP (2) | EP3572071A1 (sl) |
JP (6) | JP6133308B2 (sl) |
KR (5) | KR102452305B1 (sl) |
CN (2) | CN104114156A (sl) |
AU (1) | AU2012326370C9 (sl) |
BR (1) | BR112014009305B1 (sl) |
CA (1) | CA2852777C (sl) |
DK (1) | DK2768484T3 (sl) |
ES (1) | ES2750368T3 (sl) |
FR (1) | FR19C1063I2 (sl) |
HR (1) | HRP20191683T1 (sl) |
HU (2) | HUE045978T2 (sl) |
IL (1) | IL232161B (sl) |
LU (1) | LUC00135I2 (sl) |
NL (1) | NL301016I2 (sl) |
NO (1) | NO2019041I1 (sl) |
PL (1) | PL2768484T3 (sl) |
PT (1) | PT2768484T (sl) |
RU (1) | RU2648753C2 (sl) |
SI (1) | SI2768484T1 (sl) |
WO (1) | WO2013059133A1 (sl) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2750368T3 (es) * | 2011-10-21 | 2020-03-25 | Jazz Pharmaceuticals Res Llc | Liposomas liofilizados |
US11471401B2 (en) | 2014-08-28 | 2022-10-18 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
EP4176885A1 (en) | 2014-08-28 | 2023-05-10 | The General Hospital Corporation | Compositions and methods for treatment of neurological disorders |
US11504322B2 (en) | 2014-08-28 | 2022-11-22 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
SMT202100196T1 (it) | 2015-07-22 | 2021-05-07 | Nitto Denko Corp | Composizioni e metodi per forme liofile di nanoparticelle |
CA3219061A1 (en) * | 2015-11-11 | 2017-05-18 | Celator Pharmaceuticals, Inc. | Assays and methods for selecting a treatment regimen for a subject with leukemia |
JP2019506248A (ja) | 2016-02-26 | 2019-03-07 | ザ ジェネラル ホスピタル コーポレイション | 医療用氷スラリーの生成と送達システム及び方法 |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
AU2017423053A1 (en) * | 2017-07-10 | 2020-01-23 | Immunovaccine Technologies Inc. | Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof |
CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
MX2021015667A (es) * | 2019-06-28 | 2022-04-18 | Univ Texas | Metodo de reconstitucion de anamicina liposomica. |
WO2021016457A1 (en) * | 2019-07-24 | 2021-01-28 | The General Hospital Corporation | Methods of creating a substance with different freezing points by encapsulation |
US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
CN115252563B (zh) * | 2022-06-24 | 2024-07-12 | 石药集团中奇制药技术(石家庄)有限公司 | 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法 |
CN116003493B (zh) * | 2022-12-16 | 2025-02-28 | 常州金远药业制造有限公司 | 一种二价铜离子及阿糖胞苷的回收方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
EP0208764A4 (en) * | 1985-01-11 | 1987-10-08 | Univ California | METHOD FOR PRESERVING LIPOSOMES. |
CA1256372A (en) | 1985-04-11 | 1989-06-27 | Koichiro Miyazima | Process for producing liposome composition |
US4927571A (en) | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
US4915951A (en) | 1987-12-03 | 1990-04-10 | California Institute Of Technology | Cryoprotective reagent |
WO1990003795A1 (en) * | 1988-10-05 | 1990-04-19 | Vestar, Inc. | Method of making liposomes with improved stability during drying |
US5049392A (en) * | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
DE69720979T2 (de) | 1996-02-19 | 2004-02-26 | Amersham Health As | Thermostabilisiertes kontrastmittel |
IT1289938B1 (it) * | 1997-02-20 | 1998-10-19 | Angelini Ricerche Spa | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
ES2225178T3 (es) | 1999-07-16 | 2005-03-16 | Alza Corporation | Composicion liposomica resistente a los daños producidos por congelacion/descongelacion. |
US6984395B2 (en) * | 2001-04-11 | 2006-01-10 | Qlt, Inc. | Drug delivery system for hydrophobic drugs |
US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
CA2462376C (en) | 2001-10-03 | 2010-12-14 | Celator Technologies Inc. | Liposome loading with metal ions |
AU2002340669A1 (en) | 2001-11-13 | 2003-05-26 | Celator Technologies, Inc. | Lipid carrier compositions with enhanced blood stability |
US20050118249A1 (en) | 2001-11-13 | 2005-06-02 | Murray Webb | Lipid carrier compositions and methods for improved drug retention |
US7179484B2 (en) * | 2002-11-06 | 2007-02-20 | Azaya Therapeutics, Inc. | Protein-stabilized liposomal formulations of pharmaceutical agents |
AU2004226889B2 (en) * | 2003-04-02 | 2007-12-20 | Celator Pharmaceuticals, Inc. | Combination compositions of camptothecins and fluoropyrimidines |
JP4972545B2 (ja) | 2004-04-22 | 2012-07-11 | セレーター ファーマスーティカルズ、インク. | アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤 |
US7893338B2 (en) * | 2004-07-15 | 2011-02-22 | Creative Technology Ltd | Method of composing music on a handheld device |
CA2584583A1 (en) * | 2004-10-28 | 2006-05-11 | Alza Corporation | Lyophilized liposome formulations and method |
JP4990786B2 (ja) * | 2004-11-05 | 2012-08-01 | イネックス ファーマシューティカルズ コーポレイション | 薬物リポソーム製剤を安定化するための組成物および方法 |
WO2006055903A1 (en) | 2004-11-18 | 2006-05-26 | Celator Pharmaceuticals, Inc. | Method for loading multiple agents into delivery vehicles |
US20100189771A1 (en) | 2005-10-25 | 2010-07-29 | Lawrence Mayer | Fixed ratio drug combination treatments for solid tumors |
WO2007076117A2 (en) | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
US8092828B2 (en) | 2007-02-16 | 2012-01-10 | Celator Pharmaceuticals, Inc. | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
WO2009097011A1 (en) | 2007-08-17 | 2009-08-06 | Celator Pharmaceuticals, Inc. | Improved platinum drug formulations |
CN101878024B (zh) | 2007-11-28 | 2014-04-09 | 塞拉特药物股份有限公司 | 改良的紫杉烷递送系统 |
ES2704986T3 (es) | 2008-10-16 | 2019-03-21 | Celator Pharmaceuticals Inc | Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab |
HRP20150911T1 (hr) | 2009-12-03 | 2015-10-23 | Jiangsu Hengrui Medicine Co., Ltd. | Liposom irinotekana ili njegovog hidroklorida te postupak njegove pripreme |
US20130052259A1 (en) * | 2010-02-01 | 2013-02-28 | Yechezkel Barenholz | Liposomes comprising amphipathic drugs and method for their preparation |
ES2750368T3 (es) * | 2011-10-21 | 2020-03-25 | Jazz Pharmaceuticals Res Llc | Liposomas liofilizados |
-
2012
- 2012-10-15 ES ES12841616T patent/ES2750368T3/es active Active
- 2012-10-15 JP JP2014537142A patent/JP6133308B2/ja active Active
- 2012-10-15 HU HUE12841616A patent/HUE045978T2/hu unknown
- 2012-10-15 CN CN201280059606.1A patent/CN104114156A/zh active Pending
- 2012-10-15 KR KR1020217023773A patent/KR102452305B1/ko active Active
- 2012-10-15 BR BR112014009305-9A patent/BR112014009305B1/pt active IP Right Grant
- 2012-10-15 SI SI201231668T patent/SI2768484T1/sl unknown
- 2012-10-15 HR HRP20191683 patent/HRP20191683T1/hr unknown
- 2012-10-15 KR KR1020147012039A patent/KR102024836B1/ko active Active
- 2012-10-15 DK DK12841616.1T patent/DK2768484T3/da active
- 2012-10-15 KR KR1020207013990A patent/KR102284689B1/ko active Active
- 2012-10-15 CA CA2852777A patent/CA2852777C/en active Active
- 2012-10-15 EP EP19183846.5A patent/EP3572071A1/en active Pending
- 2012-10-15 US US14/352,662 patent/US10028912B2/en active Active
- 2012-10-15 WO PCT/US2012/060293 patent/WO2013059133A1/en active Application Filing
- 2012-10-15 CN CN201810733439.3A patent/CN108853031A/zh active Pending
- 2012-10-15 EP EP12841616.1A patent/EP2768484B1/en not_active Revoked
- 2012-10-15 KR KR1020197027220A patent/KR102113753B1/ko active Active
- 2012-10-15 KR KR1020227034406A patent/KR20220141906A/ko not_active Ceased
- 2012-10-15 AU AU2012326370A patent/AU2012326370C9/en active Active
- 2012-10-15 PT PT128416161T patent/PT2768484T/pt unknown
- 2012-10-15 RU RU2014120475A patent/RU2648753C2/ru active
- 2012-10-15 PL PL12841616T patent/PL2768484T3/pl unknown
-
2014
- 2014-04-22 IL IL232161A patent/IL232161B/en active IP Right Grant
-
2017
- 2017-04-04 JP JP2017074348A patent/JP6359717B2/ja active Active
-
2018
- 2018-02-07 US US15/891,170 patent/US10166184B2/en active Active
- 2018-05-17 JP JP2018095127A patent/JP6592556B2/ja active Active
- 2018-11-05 US US16/181,203 patent/US10835492B2/en active Active
-
2019
- 2019-09-20 JP JP2019172314A patent/JP2020007367A/ja active Pending
- 2019-10-10 HU HUS1900047 patent/HUS1900047I1/hu unknown
- 2019-10-23 FR FR19C1063C patent/FR19C1063I2/fr active Active
- 2019-10-24 LU LU00135C patent/LUC00135I2/fr unknown
- 2019-10-25 NL NL301016C patent/NL301016I2/nl unknown
- 2019-11-25 NO NO2019041C patent/NO2019041I1/no unknown
-
2020
- 2020-11-13 US US17/097,530 patent/US20210169803A1/en not_active Abandoned
-
2021
- 2021-12-03 JP JP2021196626A patent/JP7476161B2/ja active Active
-
2022
- 2022-07-13 US US17/812,414 patent/US20230172855A1/en active Pending
-
2024
- 2024-01-05 JP JP2024000732A patent/JP2024045183A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1900047I1 (hu) | Liofilizált liposzómák | |
ZA201307355B (en) | Composite elements | |
ZA201306118B (en) | Lyophilized formulations | |
PL2993263T3 (pl) | Tkanina o bardzo wysokiej sprężystości | |
EP2691581A4 (en) | joint assembly | |
GB201111183D0 (en) | Peptide | |
GB201115910D0 (en) | Peptides | |
EP2759709A4 (en) | COMPRESSOR | |
GB201619994D0 (en) | Improved fabric | |
GB2487250B (en) | Compressor | |
GB201106391D0 (en) | Novel composite | |
EP2714717A4 (en) | PHOENIXINPEPTIDE | |
GB201106377D0 (en) | Novel composite | |
GB201115014D0 (en) | Peptides | |
GB201117700D0 (en) | Improved fabric | |
PH32011000885S1 (en) | Fabric | |
PH32011000889S1 (en) | Fabric | |
PH32011000897S1 (en) | Fabric | |
PH32011000892S1 (en) | Fabric | |
PH32011000894S1 (en) | Fabric | |
PH32011000883S1 (en) | Fabric | |
PH32011000882S1 (en) | Fabric | |
PH32011000888S1 (en) | Fabric | |
PH32011000890S1 (en) | Fabric | |
PH32011000895S1 (en) | Fabric |